On June 8, 2017, SIAPS disseminated the Directorate General of Drug Administration’s (DGDA) five-year Strategic Plan (2017-2021) in the presence of the Honorable Major General Mohammad Mustafizur Rahman, Director General of DGDA. The dissemination of this plan is the result of a year-long process. In March 2016, WHO engaged with various stakeholders (SIAPS, USAID, the […]
Archive | Pharmaceutical SystemsRSS feed for this section
Introduction of an Electronic Asset Management System in Bangladesh Health Systems: Completion of the Tool Pilot in Moulvibazar District Hospital
In Bangladesh, the government health facilities face a wide variety of health-related challenges and the Ministry of Health and Family Welfare (MOHFW) must have reliable and timely data on the performances of different parts of the health system to plan, implement, and measure health interventions. Even though the MOHFW procures a large number of medical and non-medical equipment, including IT equipment, there is no systematic process of deploying, operating, maintaining, upgrading, and disposing of those assets cost-effectively. This major part of the public-sector health investment was not addressed in previous health sector programs. The MOHFW worked together with SIAPS in 2016 to address the gap in systematic procedures. They developed and piloted an electronic Asset Management System (AMS) in the 250-bed Moulvibazar District Hospital (MDH) to manage assets in different facilities from registering stage to decommissioning.
SIAPS supported the Swaziland Ministry of Health (MOH) in mobilizing key stakeholders from the Swaziland National AIDS Program and the National Tuberculosis Control Program to introduce and implement an active surveillance system for patients on ARVs and anti-TB treatment. SIAPS provided technical assistance to MOH’s National Pharmacovigilance Unit (NPVU) to develop the protocol and tools to implement the system, as well as to develop a system for recruiting patients at the HIV and TB sites.
TB patients on second-line treatment experience a significant number of adverse effects. Some TB medicines result in adverse effects that, if not continuously monitored, can become serious and/or permanent and may hinder patient adherence to treatment. A number of other risk factors can also impact the safety of patients taking TB medicines, including drug interactions […]
SIAPS, in partnership with the FDA, NTP, and LCP-NCPR, conducted a readiness assessment to determine the current information technology (IT) infrastructure, human resources, processes, and data management and quality control mechanisms available and to identify gaps in the current PV recording and reporting of patients in the seven Programmatic Management of Drug-Resistant TB (PMDT) treatment facilities implementing the 9MTR for multidrug-resistant (MDR)-TB study. The results of this assessment will provide inputs for developing the PViMS implementation plan.
An online system for monitoring and reporting cases of adverse drug reactions and lack of efficacy of medicines comprehensively addresses the need for improved access to quality, safe, and effective medicines. “The evaluation and analysis of PAIS system in Ukraine has brought out gaps and identified recommendations on operational PAIS system optimization and enhancing its […]
Key to the success of any health systems strengthening project is whether it effects broad, sustainable, institutional change. Sound strategic planning can grow a successful hospital pilot program into a nationwide health intervention that improves lives. The examples below show the SIAPS program’s work in bringing pharmaceutical systems strengthening interventions to scale. Technical Publication: Transforming Pharmaceutical […]
Technical Highlight: Strengthening Regulatory Systems in Democratic Republic of the Congo to Improve Access to Safe, Effective, and Quality Medicines
Chronic underfunding of the health sector coupled with long-term civil unrest in the Democratic Republic of the Congo (DRC) has contributed to insufficient regulatory capacity to effectively manage the registration and approval of new medicines in the country. In partnership with the USAID-funded SIAPS Program, the country’s Ministry of Health supported a number of broad interventions to strengthen DRC’s pharmaceutical regulatory system. SIAPS provides technical assistance to the three national control programs—malaria, HIV/AIDS, and tuberculosis—to improving access to quality medicines and other commodities and increase the potential for achieving desired health outcomes.
A new collection of technical briefs highlight strategic approaches, innovations, results and lessons learned in implementing systems-wide interventions to strengthen pharmaceutical systems and services in three countries: South Africa, Namibia and Ethiopia. Click on the thumbnails below to read the full technical briefs. Strengthening Namibia’s Pharmacy Sector and Workforce Strengthening the Leadership and Management of […]
By Tsion Issayas, Communications Manager for SIAPS Ethiopia. This post originally appeared on MSH’s website. Aster Amanuel Desalegn lives in Debre Markos, 190 miles from the Ethiopian capital of Addis Ababa. She is a 70-year-old mother of four and grandmother of two. Her granddaughters, Emuye, 6, and Blen, 8, live with her. On a trip back […]